Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Annals of Thoracic Surgery Année : 2017

Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery

Thibault Ronchard
  • Fonction : Auteur
Erwan Salaun
  • Fonction : Auteur
Alexis Theron
Dominique Grisoli
  • Fonction : Auteur
Nicolas Jaussaud
  • Fonction : Auteur
Frederic Collart

Résumé

Management of heparin-induced thrombocytopenia (HIT) entails cessation of heparin and initiation of a nonheparin parenteral anticoagulant such as danaparoid. Danaparoid cross-reactivity with HIT antibodies is an uncommon complication of treatment of HIT. We report the case of confirmed HIT and in vivo cross-reactivity with danaparoid, complicating severe sepsis due to an infectious endocarditis treated by cardiac surgery. (C) 2017 by The Society of Thoracic Surgeons

Dates et versions

hal-01521357 , version 1 (11-05-2017)

Identifiants

Citer

Thibault Ronchard, Erwan Salaun, Alexis Theron, Dominique Grisoli, Nicolas Jaussaud, et al.. Cross-Reactivity Between Heparin and Danaparoid Antibodies in Cardiac Surgery. Annals of Thoracic Surgery, 2017, 103 (1), pp.E9-E10. ⟨10.1016/j.athoracsur.2016.06.068⟩. ⟨hal-01521357⟩

Collections

CNRS UNIV-AMU
29 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More